Regencell describes their traditional chinese medicine ("tcm") treatments and recent efficacy trial results in new video interview on snn network

Los angeles, ca / accesswire / march 1, 2022 / snn network, the official small-, micro- and nano-cap news source™, today published a new video interview with the team from regencell bioscience holdings limited (nasdaq:rgc), including: jay lee, ceo of regencell bioscience asia limited, and paul niewiadomski, independent director. regencell is an early-stage bioscience company focuses on the research, development and commercialization of tcm for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, according to the company's website (see here: www.regencellbioscience.com).
RGC Ratings Summary
RGC Quant Ranking